Arovella secures $20m to launch blood cancer treatment trial

A Melbourne-based biotech company that is developing a treatment to help fight certain blood cancers has secured a $20 million commitment from institutional and sophisticated investors to complete phase http://www.businessnewsaustralia.com/1 of its first-on-human clinical trial of its product…